RGEN Insider Trading | Repligen Buys and Sells

RGEN Insider Trading

Insider Ownership Percentage: 1.20%
Insider Buying (Last 12 Months): $487,610.60
Insider Selling (Last 12 Months): $7,342,936.94

Repligen Insider Trading History Chart

This chart shows the insider buying and selling history at Repligen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$38kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Repligen Share Price & Price History

Current Price: $133.41
Price Change: Price Decrease of -3.71 (-2.71%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for RGEN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$133.41Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for Repligen (NASDAQ:RGEN)

97.64% of Repligen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RGEN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$686Mbought$186MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B$0$1BTotal InflowsTotal Outflows
Repligen logo
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Read More on Repligen

Today's Range

Now: $133.41
Low: $130.41
High: $137.05

50 Day Range

MA: $154.21
Low: $133.41
High: $174.24

52 Week Range

Now: $133.41
Low: $113.50
High: $184.98

Volume

856,653 shs

Average Volume

673,469 shs

Market Capitalization

$7.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Who are the company insiders with the largest holdings of Repligen?

Repligen's top insider investors include:
  1. Anthony Hunt (CEO)
  2. Anthony Hunt (Director)
  3. Karen A Dawes (Director)
  4. Christine Gebski (Insider)
  5. Ralf Kuriyel (VP)
  6. James Bylund (COO)
  7. Martin D Madaus (Director)
  8. Margaret Pax (Director)
Learn More about top insider investors at Repligen.

Who are the major institutional investors of Repligen?

Repligen's top institutional shareholders include:
  1. Price T Rowe Associates Inc. MD — 12.74%
  2. Vanguard Group Inc. — 9.10%
  3. Champlain Investment Partners LLC — 2.75%
  4. Impax Asset Management Group plc — 1.88%
  5. Alliancebernstein L.P. — 1.80%
  6. Conestoga Capital Advisors LLC — 1.69%
Learn More about top institutional investors of Repligen stock.

Which institutional investors are selling Repligen stock?

Within the last quarter, RGEN stock was sold by these institutional investors:
  1. Federated Hermes Inc.
  2. Bank of America Corp DE
  3. Eversept Partners LP
  4. First Light Asset Management LLC
  5. Squarepoint Ops LLC
  6. Two Sigma Investments LP
  7. Riverbridge Partners LLC
  8. Nuveen Asset Management LLC
During the last year, company insiders that have sold Repligen company stock include:
  1. Anthony Hunt (CEO)
  2. Anthony Hunt (Director)
  3. Karen A Dawes (Director)
Learn More investors selling Repligen stock.

Which institutional investors are buying Repligen stock?

During the previous quarter, RGEN stock was bought by institutional investors including:
  1. Price T Rowe Associates Inc. MD
  2. Point72 Asset Management L.P.
  3. Groupama Asset Managment
  4. Alyeska Investment Group L.P.
  5. Raymond James Financial Inc.
  6. Raymond James Financial Inc.
  7. Allspring Global Investments Holdings LLC
  8. Alliancebernstein L.P.
Within the previous year, these company insiders have bought Repligen stock:
  1. Anthony Hunt (CEO)
  2. Anthony Hunt (Director)
  3. Karen A Dawes (Director)
Learn More investors buying Repligen stock.